Pharvaris (PHVS) Stock
Clinical stage biotech developing oral treatments for rare conditions. Here's the price, business snapshot, and what's worth knowing about Pharvaris in October 2026.
Pharvaris NV (PHVS) is a clinical-stage biopharmaceutical company developing small‑molecule therapies for bradykinin‑mediated disorders such as hereditary angioedema (HAE). Investors should know it focuses on oral treatment candidates and early‑to‑mid stage clinical programmes, so value is driven mainly by trial outcomes, regulatory milestones and potential partnerships or licensing deals. The company’s market capitalisation is around $1.54bn, reflecting investor expectations for successful development but also the risks typical of clinical-stage biotech: trial setbacks, regulatory uncertainty and funding needs. Financial runway, data readouts and commercial strategy are key variables to watch. This summary is for educational purposes only and not personal financial advice; investors should assess their own circumstances, consider diversification and be aware that biotech stocks can be volatile and may lose value.
Pharvaris (PHVS) Stock Forecast
Analyst price target, next 12 months
$48.22
+53.5% vs today's $31.41
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Pharvaris have a consensus 12-month target of $48.22, above the current price of $31.41.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying PHARVARIS NV's stock, anticipating a significant increase in value.
Financial Health
Pharvaris NV has a strong cash flow and a solid book value per share, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Oral therapy focus
Developing oral small‑molecule candidates may expand patient convenience and market reach, though clinical success is not guaranteed and trials carry risk.
Data-driven value
Share price sensitivity is often linked to trial readouts and regulatory milestones; positive results can lift sentiment, but outcomes can vary.
Partnership potential
Collaborations or licensing deals could accelerate development and commercial reach, while financing needs and competition remain key considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
